Fig. 1.

Lymph transport is delayed in the lower limbs of presymptomatic and postsymptomatic SOD1-G93A ALS mice. (A) Cartoon to the left shows the site of injection of FITC-Dextran in the shaved right leg paw and the area in the right hindlimb monitored under a fluorescent scope after that (boxed). The right panel shows time-lapse sequential images taken every 5 min after FITC-Dextran injection, showing the peripheral lymphatics (arrows) in the right hindlimb (outlined within dashed lines) of postnatal day (p)50 and p120 non-transgene-carrier (NC) control and amyotrophic lateral sclerosis (ALS) SOD1-G93A mice. (B) Average time taken to attain maximum fluorescence intensity, which was longer on average for the ALS mice, was measured and plotted for control and ALS groups. (C) Average fluorescence intensity in a standardized area was quantified in ImageJ at each time point up to 25 min for control and ALS groups. n=6/genotype/disease stage, all males. NC animals of the same age were used as controls for p50 and p120 ALS mice, respectively. *P<0.05. Values are presented as mean±s.e.m. Means were compared using Mann–Whitney test. Scale bars: 410 µm.